US 11,746,119 B2
Cardiopathy-reducing phosphodiester lipids
James McChesney, Etta, MS (US); Annie Bouchard, Stoke (CA); Saravanan Kappusamy, Bangalore (IN); John Kallikat Augustine, Bangalore (IN); and Daniel Emil Levy, San Mateo, CA (US)
Assigned to SignPath Pharma, Inc., Sandy, UT (US)
Filed by Signpath Pharma, Inc., Sandy, UT (US)
Filed on Nov. 5, 2021, as Appl. No. 17/520,287.
Application 17/520,287 is a continuation of application No. 17/191,214, filed on Mar. 3, 2021.
Application 17/191,214 is a continuation of application No. 16/452,858, filed on Jun. 26, 2019, granted, now 10,975,111, issued on Apr. 13, 2021.
Claims priority of provisional application 62/690,196, filed on Jun. 26, 2018.
Prior Publication US 2022/0056057 A1, Feb. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 9/09 (2006.01); A61P 9/00 (2006.01); C07F 9/655 (2006.01); A61K 45/06 (2006.01)
CPC C07F 9/09 (2013.01) [A61P 9/00 (2018.01); C07F 9/65515 (2013.01); A61K 45/06 (2013.01)] 12 Claims
 
1. A compound of Formula:

OG Complex Work Unit Chemistry